Cohen I Glenn, Marks Mason
Harvard Law School.
Florida State University College of Law.
Am J Bioeth. 2025 Jan;25(1):6-15. doi: 10.1080/15265161.2025.2434398. Epub 2025 Jan 13.
Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different from other treatments that they warrant special consideration in how they are researched, regulated, commercialized, and administered. Others argue that psychedelic medicines show clinical potential, but they should be treated like other medical interventions. In other words, identical standards should apply. This article analyzes whether psychedelic medicines warrant special consideration from a regulatory and ethical perspective.
对迷幻药的研究正在复兴。一些临床医生、科学家和伦理学家认为,迷幻药与其他治疗方法有很大不同,因此在研究、监管、商业化和管理方式上值得特别考虑。另一些人则认为,迷幻药显示出临床潜力,但它们应与其他医疗干预措施一视同仁。换句话说,应适用相同的标准。本文从监管和伦理角度分析了迷幻药是否值得特别考虑。